InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（3 笔）
内部人交易记录
高级管理人员已披露买入
0
已披露卖出
3
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the complete record of transactions filed by Perry Andrew, Directeur Commercial. Director active across 1 company, notably G1 Therapeutics, Inc.. Aggregated, 9 reports have been published. Breakdown: 0 buy · 3 sells. Total volume traded: €40k. History available since 3 January 2022. The latest transaction was filed on 5 July 2024 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Perry Andrew
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报9 总计
16,100 股Common StockSEC:0000950170-24-107787:0
1,337 股@ US$2.50777.7% 占其流量Common StockSEC:0001562180-24-005660:0
35,000 股0Common StockSEC:0001562180-24-005608:0
8,151 股@ US$4.788890.3% 占其流量Common StockSEC:0001562180-24-004064:0
33,570 股0Common StockSEC:0001562180-24-000325:0
355 股@ US$2.45372.0% 占其流量Common StockSEC:0001562180-23-005819:0
35,000 股0Common StockSEC:0001562180-23-004095:0
16,100 股0Common StockSEC:0001562180-23-000253:0
6,000 股0Common StockSEC:0001562180-22-000308:0
9 条申报中的 9 条
About Perry Andrew
Perry Andrew is Directeur Commercial and Chief Commercial Officer at G1 Therapeutics, Inc. Across 9 filings, the 9 sampled filings cover the period from 2022-01-05 to 2024-09-18, with EUR 0 in buys and EUR 40067 in sells.
